Key facts
- It has raised $7.6M across 5 recorded rounds; the latest was Seed Round ($3.4M) in Dec 2016.
- Notable investors include B. Riley Venture Capital, Thornapple River Capital.
- AltaThera Pharmaceuticals has filed 7 Form Ds with the SEC since 2015, most recently Aug 2019 ($1.5M sold to 2 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 5 rounds
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for AltaThera Pharmaceuticals
Funding rounds
5 roundsAbout AltaThera Pharmaceuticals
Developer of specialty pharmaceuticals intended to serve pediatric cardiac patients and adult atrial fibrillation patients with effective treatments. The company's product focuses on critical care and alternative therapeutics for unmet medical needs and develops therapies for critical care patients and patients with rare disorders, enabling healthcare providers and hospitals to cure severe disorders improve patients' lives, and help optimize the delivery of quality care.
- Sector
- Healthcare
- HQ
- Chicago, IL, United States
- Founded
- 2012
- Employees
- 46
- Website
- altathera.com/
- Ownership
- Privately Held (backing)
AltaThera Pharmaceuticals doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in AltaThera Pharmaceuticals shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on AltaThera Pharmaceuticals in its N-PORT filings yet. We sweep new filings monthly.